Evidence for an Alternatively Spliced MITF Exon 2 Variant  by Simmons, Jacinta L. et al.
nickel binding has not been reported.
Unfortunately, SC protein extraction
must be performed under denaturing
conditions, and the presence of resident
proteins that need their secondary or
tertiary structure for nickel binding
could not be evaluated. Moreover, as
the cornified envelope resists breakdown
into its protein constituents, they are
inaccessible for analysis. Finally, the
setup did not allow for assessment of
nickel binding by free amino acids.
In summary, we demonstrate that
filaggrin derived from both SC and full
epidermis binds nickel. Other epidermal
proteins may bind nickel, but filaggrin is
a strong, denaturation-resistant chelator,
and the relevance of the other proteins,
e.g., for the accumulation of nickel
in the SC, remains unclear. As filaggrin
null mutations are associated with an
increased risk of allergic nickel der-
matitis in European populations, this
study provides a possible link bet-
ween genetics, protein expression, and
function.
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TO THE EDITOR
Alternative splicing of exon 1 in the
microphthalmia-associated transcription
factor (MITF) gene gives rise to a family
of transcription factors that differ only in
exon 1 sequence (Steingrimsson et al.,
2004). Each MITF isoform is associated
with a specific promoter and each
unique promoter/isoform combination
results in MITF expression in a different
cell lineage. In the melanocytic cell
lineage, MITF is expressed from the
M-promoter, leading to a transcript con-
taining exon 1 M; therefore, this isoform
is termed MITF-M. The amplification of
MITF-M occurs in 10–20% of all mela-
noma cases, and it has been suggested
that MITF-M may be a prognostic mar-
ker for poor survival in melanoma
(Garraway et al., 2005; Ugurel et al.,
2007). Recently, a germline mutation in
MITF (E318K) has also been shown to
contribute to increased susceptibility to
melanoma (Bertolotto et al., 2011;
Yokoyama et al., 2011). The MITF
signaling pathway has further been
shown to contribute to melanoma
susceptibility. A recent study identified
frequent somatic mutations in both
MITF and its regulator SOX10, with
14% of primary and 20% of metastatic
melanoma containing mutations in
these genes (Cronin et al., 2009).
Recently, an isoform of MITF-M that is
alternatively spliced at exons 2 and 6
has been reported. This shortened iso-
form, termed MITF-MDel, was expressed
at a detectable level only in melanocytesAccepted article preview online 14 October 2013; published online 14 November 2013
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and melanoma cells and was predicted
to be a prognostic biomarker for mela-
noma (Wang et al., 2010). The functio-
nal significance of MITF-MDel in either
melanocyte or melanoma development
is still unknown and debated.
Exon 2 of MITF-M contains a ‘‘cryptic
splice donor site’’, which divides the
exon into 2 A (60 bp) and 2B (168 bp).
MITF-MDel was found to be lacking
exon 2B (Hallsson et al., 2000; Wang
et al., 2010). Mice carrying a homozy-
gous germline deletion of exon 2B
(MITFmi-bws) have a mild pigmentation
phenotype, whereas others have shown
that exon 2B is dispensable for melano-
cyte development (Hallsson et al., 2000;
Bismuth et al., 2005; Bauer et al., 2009).
Phosphorylation of a conserved serine
residue (S73) contained within exon 2B
has been proposed to both enhance the
transcriptional activity and decrease the
stability of the protein (Wu et al., 2000).
It is therefore possible that the absence
of S73 could contribute to the pigmen-
tation defects observed in MITFmi-bws
mice and to any functional conseque-
nces of MITF-MDel expression.
While cloning MITF-M from cultured
human melanocytes, we found a third
shortened transcript that we sequenced
and aligned against both MITF-M and
MITF-MDel (Figure 1a). This revealed a
75 bp in-frame deletion in exon 2 com-
mencing at the cryptic splice donor site
at the start of exon 2B; here, we call this
alternatively spliced isoform MITF-M2C.
Alignment of the predicted protein
sequence for MITF-M2C with MITF-M
and MITF-MDel showed a deletion of
25 amino acids with those outside
of the deletion remaining unaffected
(Figure 1b). No previously identified
functional protein components are con-
tained within the deletion, and it is
therefore possible that this transcript
does not encode a protein with unique
function. Importantly, the key residue
for phosphorylation of S73 remains
encoded in the MITF-M2C transcript.
We cannot, however, rule out any
change in the secondary structure and,
therefore, potential function in the
MITF-M2C protein.
To determine whether MITF-M2C was
widely expressed, we performed quan-
titative real-time reverse-transcriptase–
PCR (qRT–PCR) to measure each of
the exon 2 variants across a panel of
cell lines and patient tumor specimens.
The PCR experiment was designed
with one common forward primer and
three separate reverse primers, which
differentiated between the transcripts
on the basis of the sequence across
the exon 2 splice junction (Supple-
mentary information online). Analysis
of 19 human cell lines, including 18
metastatic melanoma, one primary
melanoma (MM200) and normal human
melanocytes, revealed a low-level
expression of MITF-M2C across all cell
lines tested (Figure 2a). Metastatic mel-
anoma samples representing brain, skin
(regional lymph node), and kidney
metastases derived from 6 patients
similarly showed a low-level expression
of MITF-M2C in all specimens
(Figure 2b). Sequencing of the MITF-
M2C PCR product confirmed specific
amplification and shows the MITF-M2C
splice junction (Figure 2c). Western blot
analysis provides some evidence that
the protein may be expressed in both
melanocytes and melanoma cell lines
(Supplementary Figure S1 online). We
were able to detect minor bands of a
smaller apparent molecular weight than
MITF-M. As the antibody used to detect
MITF was raised against the N-terminal
region, which is common to all three
isoforms, we are unable to definitively
identify and distinguish MITF-M2C and
MITF-MDel. However, the relative
abundance of the detected proteins
was consistent with levels detected
by qRT-PCR, supporting our tentative
identification of these isoforms.
The results presented here show that
this previously unreported splice variant
of MITF-M is expressed at a lower level
in a variety of metastatic melanoma cell
lines and tumors. These results also
indicate that MITF-M2C may be a com-
mon feature of cells and tissues that
express MITF-M. On the basis of the
a
b
Figure 1. Microphthalmia-associated transcription factor (MITF)-M isoform alignments. (a) Alignment of
exons 1–3 of MITF-M (NM_000248.3) with MITF-Mdel (GU355676.1) and MITF-M2C. Alternative exons
are indicated in blue and deleted bases with a dash ( ). (b) MITF-M2C protein prediction aligned with
MITF-M (NM_000239.1) and MITF-Mdel (ABD90411). Alignment corresponds to exons 1–3, and
alternative exons are indicated in blue and deleted amino acids with a dash.
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current understanding, we feel that there
may be little physiological significance
of MITF-M2C expression in either mel-
anogenesis or melanoma development.
However, given the low expression
level of this transcript, it will be inter-
esting to see whether MITF-M2C is
detected in high-throughput sequencing
studies in melanoma tumor samples.
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Figure 2. Detection of microphthalmia-associated transcription factor (MITF)-M isoforms in human
melanocytes and melanoma cell lines. Quantitative reverse transcription PCR for MITF-M (white), MITF-
Mdel (gray), and MITF-M2C (black), normalized to glyceraldehyde-3-phosphate dehydrogenase. (a)
Human melanoma and melanocyte cell lines. MM200 was derived from a primary tumor. (b) Human
metastatic melanoma tumors isolated from the brain (Br), skin/lymph node (Sk), and kidney (Ki). Error bars
represent standard deviation, n¼X2. (c) An MITF-M2C reverse transcription PCR product was sequenced
to confirm specific amplification of this isoform. The chromatogram shows the splice boundary, the
location of the reverse PCR primer is underlined in black, and the bases at the splice junction are boxed
in red.
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